ARCH Venture Partners

Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs

Neumora Therapeutics unveiled $500 million in capital and a research partnership with Amgen. The startup analyzes neurological data to inform its drug research and development; President and Chief Operating Officer Lori Lyons-Williams said researching psychiatric drugs and neurodegenerative drugs within the same company allows brain insights from one area to inform the other.

Former Starbucks Exec, White House Official Engskov to Lead Home Health Care Startup

Kris Engskov — an official in the Bill Clinton White House, a long-time executive with Starbucks and most recently president of senior living provider Aegis Living — is set to lead a new company in the home health care space. “COVID taught us how much can be done from home,” Engskov told Home Health Care …

Former Starbucks Exec, White House Official Engskov to Lead Home Health Care Startup Read More »

Backed by $92M, startup Interline aims to shed new light on protein communities

Interline Therapeutics has technology that shows how proteins interact as communities, paving the way for the discovery of new drugs. CEO Zachary Sweeney, a Denali Therapeutics veteran, said the startup will use the $92 million in funding to advance programs in cancer and inflammatory diseases.

Glympse Bio raises more than $46M in Series B round for biosensor technology

The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.